Opinion Statement

The conceptual shift of our understanding of migraine from a vascular disorder to a brain disorder has dramatically altered the approach to the development of new medicines in the field. Current pharmacologic treatments of acute migraine consist of nonspecific and relatively specific agents. Migraine-specific drugs comprise two classes, the ergot alkaloid derivatives and the triptans, serotonin 5-HT1B/1D receptor agonists. The ergots, consisting of ergotamine and dihydroergotamine (DHE), are the oldest specific antimigraine drugs available and are considered relatively safe and effective. Ergotamine has been used less extensively because of its adverse effects; DHE is better tolerated. The triptan era, beginning in the 1990s, was a period of considerable change, although these medicines retained vasoconstrictor actions. New methods of delivering older drugs include orally inhaled DHE and the transdermal formulation of sumatriptan, both currently under study. Novel medicines being developed are targeted at neural sites of action. Serotonin 5-HT1F receptor agonists have proven effective in phase II studies and have no vascular actions. Calcitonin gene-related peptide (CGRP) receptor antagonists are another promising nonvasoconstrictor approach to treating acute migraine. Olcegepant (BIBN4096BS) and telcagepant (MK-0974) have been shown to be safe and effective in phase I, II, and (for telcagepant) phase III clinical trials. Other targets under investigation include glutamate (AMPA/kainate), TRPV1, prostanoid EP4, and nitric oxide synthase. With new neural targets and the potential for therapeutic advances, the next era of antimigraine medications is near.

Introduction

Migraine is a common and disabling neurologic disorder with complex neurobiology that has fascinated physicians and scientists for centuries. The pathogenesis was once considered vascular, and this vascular theory gained momentum as a consequence of experimental work done by Harold Wolff and colleagues [1]. They showed that infusions of intravenous ergotamine, a vasoconstrictor, resulted in a decrease in both headache and temporal pulsations in some patients. Conversely, dihydroergotamine has been shown to inhibit second-order trigeminal neurons in the trigeminocervical complex [2], suggesting that these drugs have a neural mode of action.

We now know that although blood vessel changes may occur during attacks, they are not the inciting mechanism of an attack, and the vessel caliber does not change in parallel with therapy [3]. Premonitory symptoms such as fatigue, concentration impairment, and mood change can occur a day before the headache, suggesting brain involvement at an early stage of the attack. Typical attacks are characterized by the perception of throbbing head pain aggravated by movement and accompanied by nausea, vomiting, or both. The broad dysfunction in sensory processing during an acute attack manifests itself clinically as photophobia, phonophobia, or osmophobia. Taken together, migraine is best explained by a dysfunction in the neuromodulatory structures of the brainstem, evidenced by PET studies that have shown an area of activation in the dorsolateral pons [4]. Ultimately, the recognition of migraine as a brain disorder has been important in understanding the disease and suggesting novel neural targets.

Types of acute migraine agents

Acute migraine treatments consist of migraine-specific and nonspecific agents, although it must be acknowledged that the specificity is relative, as triptans are also excellent treatments for cluster headache. Nonspecific agents such as NSAIDs, acetaminophen (paracetamol), and aspirin are effective [5], Class I], but gastrointestinal effects can often limit their use. Opioids may be useful for some patients, but their use should be restricted because of the potential for medication overuse headache and addiction. Compounds containing butalbital have little obvious utility. Ergotamine and DHE are migraine-specific medications with a long history of effectiveness, and the introduction of the triptans, serotonin 5-HT1B/1D receptor agonists, was revolutionary. Sumatriptan was the first available triptan and was followed by six others: rizatriptan, eletriptan, almotriptan, zolmitriptan, naratriptan, and frovatriptan. These are highly effective medications that have transformed the lives of many patients suffering with migraines [6, Class I]. The triptans have enhanced clinical practice, our basic pharmacologic understanding, and health care delivery systems. Nevertheless, only one third of patients in clinical trials are pain-free 2 h after taking a triptan orally, so novel treatment options are needed [6, Class I].

Aims of acute migraine treatment

As migraine contributes to sick days, loss of productivity, and emergency room visits, there is considerable need for improvement in medicines to control acute attacks. The effectiveness of acute treatments can be measured clinically using migraine diaries. In randomized, double-blind, placebo-controlled trials, optimal acute migraine treatments are determined by well-established efficacy, tolerability, and safety profiles determined by end points introduced during the triptans era [7]. For acute treatment, patients ultimately want rapid pain relief that is long-lasting. Perhaps the most patient-centered measure is the composite end point known as sustained freedom from pain with no adverse events (SNAE), which is defined as freedom from pain within 2 h, with no use of rescue medication or headache recurrence within a minimum period of 24 h and no adverse events [8]. With these aims in mind, treatment can potentially transform the quality of life of the migraine sufferer and minimize the societal impact of the disorder.

Treatment

Pharmacologic treatment

Emerging therapies

  • The development of new compounds is long overdue. Though the triptan era has profoundly expanded the therapeutic armamentarium in clinical practice, inadequate response, tolerability, and contraindications to their use in patients with a history of stroke, myocardial infarction, or coronary artery disease risk equivalents remain major issues (though probably overestimated). For this reason, compounds that are not vasoactive may hold the promise of wider therapeutic potential. Although the pharmacotherapy of migraine has advanced in parallel with our understanding of the pathophysiology of the disease, it is clear that more experimental work is necessary to identify new targets and to develop more efficacious antimigraine compounds.

  • Though human migraine models have been paramount in proving efficacy and tolerability, much work remains in deciphering the relationship between the agents of provocation (eg, nitric oxide donors, CGRP, 5-HT, or prostaglandins) the cascade of events, and their mechanistic role. As migraine is clearly a genetic disorder, the use of genome-wide studies and pharmacogenetics may be fruitful. Despite these challenges, the clinical use of nonvasoconstrictor antimigraine compounds is near.

  • This article aims to review investigational compounds and devices (Table 1) currently undergoing clinical trials for acute migraine attacks. The targets reflect our current understanding of the essentially neural basis of migraine.
    Table 1

    Emerging therapies for acute migraine

    Compounds

    Treatment class

    Clinical phase

    COL-144

    5-HT1F receptor agonist

    Phase II–complete

    Telcagepant (MK-0974)

    CGRP receptor antagonist

    Phase III–complete

    BI 44370

    CGRP receptor antagonist

    Phase II–complete

    BGG492

    AMPA receptor antagonist

    Phase II

    Tezampanel (LY-293558)

    AMPA and kainate receptor antagonist

    Phase II

    LY466195a

    GLUK5 kainate receptor antagonist

    Phase II

    SB-705498

    TRPV1 receptor antagonist

    Phase II–complete

    NXN-188

    Neuronal nitric oxide synthase (nNOS) inhibition & 5-HT1B/D agonist

    Phase II

    GW274150

    Inducible nitric oxide synthase inhibition

    Phase II–complete

    BGC20-1531

    Prostanoid EP4 receptor antagonist

    Phase II, phase I

    aNot yet listed on the ClinicalTrials.gov website

    AMPA α-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid, CGRP calcitonin gene-related peptide, TRPV1 transient receptor potential vanilloid subfamily member 1

Serotonin receptor agonists

Seven families of 5-HT receptors have been identified. The 5-HT1 receptors consist of at least five receptor subtypes and represent the largest subfamily. Migraine patients have low central and interictal 5-HT plasma levels and increased levels and release of a major 5-HT metabolite, 5-hydroxyindole acetic acid, 5H1AA, during acute attacks [9]. Based on these observations of 5-HT metabolism, the potent 5-HT1B/1D receptor agonists were developed. The trigeminal ganglion and the free trigeminal nerve fibers contain mainly 5-HT1D receptors, whereas the small meningeal vessels contain mainly 5-HT1B receptors. Triptans may exert their effects through presynaptic inhibition of the peripheral trigeminovascular neurons or through central action along the trigeminonociceptive pathways [6]. Though earlier events lead to the initiation of an attack, activation of 5-HT1B/1D and 5-HT1F receptors by some triptans results in inhibition of the trigeminovascular system, possibly by blocking the release of calcitonin gene-related peptide (CGRP), as opposed to vasoconstriction, which is likely a parallel phenomenon [10].

The 5-HT1D receptor agonists are potent inhibitors of dural neurogenic protein plasma extravasation without any vasoconstrictor effects. Therefore, it is conceivable that the 5-HT1D receptor agonists may be potential therapies. Unfortunately, PNU-142633, a 5-HT1D agonist, was ineffective in clinical studies. In retrospect, this result may have been predicted, as PNU-142633 is a relatively weak agonist when compared with sumatriptan, and it also has poor blood-brain barrier penetration [11]. It remains questionable whether more potent 5-HT1D agonists will be the answer, as dural protein plasma extravasation is not a major player in migraine pathogenesis [12].

The 5-HT1F receptor is a potential neural target distributed in the trigeminal ganglion and the trigeminal nucleus caudalis. 5-HT1F receptor activation inhibits trigeminal nucleus Fos activation, a marker of neuronal activation, and neuronal firing without vasoconstrictor effects. When tested, the potent 5-HT1F agonist, LY-334370 was effective in acute migraine, but at doses with adverse effects on the central nervous system [13]. Unfortunately, its development was halted by nonhuman toxicity unrelated to the migraine mechanism. Another 5-HT1F receptor agonist, COL-144, is orally bioavailable, and a placebo-controlled, dose-ranging phase II study was positive [14].

Calcitonin gene-related peptide receptor antagonists

Beyond the triptans, the CGRP receptor antagonists seem to be the most promising non-vasoconstrictor acute migraine treatments. CGRP is a neuropeptide product produced by alternative RNA splicing of the calcitonin gene. CGRP receptors are found on meningeal blood vessels, trigeminal ganglion and afferents, in the periaqueductal gray, and in other areas of the brain associated with migraine [15]. Stimulation of the trigeminal ganglion can result in elevations of CGRP and substance P [16], but only CGRP was significantly elevated in the external jugular veins in patients during an acute attack of migraine [17]. These observations contributed to the development of CGRP receptor antagonists (olcegepant [BIBN4096BS, given intravenously] and telcagepant [MK-0974, given orally], also called the gepants) in the treatment of acute migraine attacks.

Olcegepant has been shown to be effective and well tolerated in phase II trials [18], and for telcagepant phase III clinical trials for acute treatment [19••]. In a recent large, multicenter, randomized controlled trial of telcagepant (150 mg or 300 mg) versus zolmitriptan (5 mg) or placebo, 300 mg of telcagepant was more effective than placebo for pain freedom, pain relief, and absence of photophobia, phonophobia, and nausea. The efficacies of 300 mg of telcagepant and 5 mg of zolmitriptan were similar, and both were more effective than 150 mg of telcagepant. Unfortunately, a preventive study of telcagepant in migraine resulted in elevated liver transaminases in some participants, so dosing restrictions may be required in clinical practice.

Glutamate receptor antagonists

Glutamate is the most important excitatory neurotransmitter, and it plays a pivotal role in conveying sensory and nociceptive information in the brain and the spinal cord [20•]. Glutamate acts through ionotropic glutamate receptors (iGluR) (ligand-gated channels) and G-protein coupled metabotropic receptor families. The iGluR receptors are divided in three subtypes: N-methyl-D-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoazolepropionic acid (AMPA), and kainate. Glutamate receptors are distributed within the pain relay structures important for migraine pathophysiology. In addition, glutamate neurons in the trigeminal ganglia mostly express 5-HT1B/1D/1F receptors, which have been proposed to modulate glutamate release [21]. Furthermore, the excitatory neurotransmitter has been implicated in migraine pathophysiology, with key roles in trigeminovascular activation, central sensitization, and cortical spreading depression (CSD) [22].

Nonselective blockade of AMPA and kainate receptors with 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) has been shown to block trigeminocervical complex cell firing in response to electrical stimulation of dural structures in rats [23]. When tested in a small clinical trial, LY-293558, an AMPA and kainate receptor antagonist, and sumatriptan were both effective in treating headache and met all primary end points when compared with placebo [24]. LY-293558, now named tezampanel, has been studied in phase II trials. In a recent experiment with a model of neurogenic vasodilatation (a model involving reproducible vasodilatation in response to CGRP release after electrical stimulation of the dura mater around the middle meningeal artery), iGluR5 receptor activation inhibited dural vasodilatation, suggesting that the kainate receptor antagonist may exert antinociceptive effects centrally [25]. Following this rationale, LY466195, a GLUK5 kainate receptor antagonist, may be a suitable compound. Another glutamate receptor blocker, BGG492, targets AMPA subtypes and is undergoing phase II clinical trials. There is evidence for a role for the AMPA receptor in nociceptive trigeminovascular transmission, as blockade with GYKI 52466 produced a dose-dependent inhibition of trigeminovascular evoked responses in the trigeminocervical complex of cats [26].

The results from a recent genome-wide association study implicates a sequence variant on 8q22.1, which is flanked between two genes involved in glutamate homeostasis, in the inheritance of migraine [27••]. The effect was strongest for migraine with aura only, but it was also seen in the all-migraine group. In essence, it is expected that pharmacologic approaches targeting glutamate receptors may alter migraine pathogenesis and reveal a novel nonvasoactive therapeutic approach. An important general caveat to targeting glutamate receptors is the potential for adverse effects, given their wide distribution within the central nervous system.

Transient receptor potential vanilloid (TRPV1) receptor antagonists

The transient receptor potential vanilloid subfamily member 1 (TRPV1) antagonist, SB-705498, has been investigated in a phase II trial. TRPV1 comprises nonselective cation channels activated by capsaicin (the pungent ingredient in chili peppers), heat, and acid. They are located in both the central and peripheral trigeminal system [28]; more specifically, TRPV1 immunoreactivity has been found in 16% of human trigeminal ganglion cells, with a small proportion of TRPV1 receptors showing colocalization with CGRP receptors [29]. Inhibition of TRPV1 also has been shown to prevent and reverse central sensitization [30]. Antimigraine action also seems plausible, as capsaicin-induced dilatation is inhibited by the CGRP receptor blockade [31]. However, a study of neurogenic dural dilatation in rats using a selective brain-penetrant TRPV1 antagonist, A-993610, was able to block capsaicin-induced dural dilatation but failed to show an effect on neurogenic dural dilatation [32]. A potential role for the TRPV1 receptor in trigeminally mediated sensitization has recently been demonstrated [33], but of itself it is probably not sufficient to indicate antimigraine potential. The therapeutic gain is not yet known.

Nitric oxide synthesis inhibition

Nitric oxide (NO) is a gaseous molecule produced from nitric oxide synthase (NOS). NOS has three different isoforms: endothelial (eNos), neuronal (nNos), and inducible (iNos). NO regulates arterial diameter in cerebral and extracerebral vessels and has been implicated in the pathogenesis of migraine and other pain states [34]. NO has been proposed to activate trigeminovascular fibers and thus release CGRP [35].

Historically, vasodilatation induced by glyceryl trinitrate has been considered the underlying mechanism of its triggering migraine attacks, but several observations suggest that this may be an epiphenomenon. For one, nitroglycerin provocation triggers premonitory symptoms in many patients that are similar to those occurring with spontaneous attacks, and they occur well after any presumably vascular changes [36]. In addition, careful monitoring of cranial vessels using MR angiography shows that NO-induced vasodilatation is long resolved when migraine starts [37]. In view of these observations, NO production blockade has been evaluated as a potential nonvasoconstrictor treatment option.

The inhibition of trigeminocervical complex Fos expression with NOS blockade by Nω-nitro-L-arginine methyl ester (L-NAME) has been demonstrated, suggesting a possible approach to therapy [38]. Previously, NO synthesis inhibition showed positive results in a small cohort of patients [39], and GW274150, a highly selective iNOS inhibitor, showed analgesic effects [40]. Results of a recent randomized, single-blind, placebo-controlled, adaptive clinical trial failed to demonstrate efficacy for GW274150 in acute migraine [41]. NXN-188 is an nNOS inhibitor and a 5-HT1B/1D receptor agonist that was also ineffective in a previous phase II study [42]. A more recent phase II, multicenter, randomized controlled study of NXN-188 showed positive results, however, and most adverse events were mild to moderate in severity; none were serious [43]. This combination may be a logical target, as prolonged administration of triptans may result in increased expression of nNOS, CGRP, and cutaneous allodynia, the clinical correlate of central sensitization, a process that may be reversed by nNOS inhibition [44].

Prostanoid receptor antagonists

BGC20-1531 is a prostanoid EP4 receptor competitive antagonist currently undergoing phase II trials. Prostaglandin E2 (PGE2) is considered an important mediator of pain and inflammation, and it may play a role in migraine pathophysiology. In vitro studies of cultured rat trigeminal neurons show that prostanoids can induce CGRP release [45]. In addition, elevated PGE2 levels have been demonstrated in the jugular venous blood [46] during acute migraine attacks.

PGE2 acts through EP receptors: EP1 and EP3 receptor activation mediate smooth muscle contraction, whereas EP2 and EP4 receptor activation exerts vascular smooth muscle relaxation [47]. EP4 receptors have been shown to be involved with prostaglandin-induced cerebral vascular dilatation. As vasodilatation is more likely a parallel phenomenon in acute migraine, the EP4 receptor association with pain is likely to be a consequence of an independent antihyperalgesic effect. An antihyperalgesic effect can be appreciated with an EP4 receptor antagonist in animal models of inflammatory pain [48].

It is not clear whether EP4 receptor antagonists will be more effective than nonspecific anti-inflammatory agents used in the treatment of migraine. NSAIDs and acetylsalicylic acid are first-line acute migraine treatments. They reduce headache by inhibiting cyclo-oxygenase, an enzyme that catalyzes the conversion of arachidonic acid to prostaglandin H2, a precursor to inflammatory mediators, the prostanoids. If proven effective, however, EP4 receptor antagonist medications may be an important nonvasoconstrictor treatment option.

New approaches to old drugs

  • The ergot alkaloids are old but effective specific antimigraine drugs that are used worldwide. Ergotamine tartrate (ET) was the first pure ergot alkaloid to be marketed for migraine treatment. Dihydroergotamine (DHE) was synthesized later, in 1943. Because of problems with tolerability, the potential for vasoconstriction, the poor bioavailability of oral formulations, and the modest improvements with intranasal forms, its clinical use has been limited.

  • Likewise, the triptans have transformed the lives of many, but gastroparesis, nausea, and vomiting are issues that interfere with absorption.

  • In addition to limitations associated with the route of administration, migraine-specific agents are being tested to determine the responsiveness to clinical phenotypes. The triptan responsiveness of allodynia has been examined to some extent with almotriptan [49, Class I], and the effects of intranasal DHE are under study (Table 2). It will be interesting to see how these symptoms, thought to be secondary to migrainous biology, respond to treatment.
    Table 2

    Old drugs, new approaches for acute migraine

    Compounds

    Treatment class

    Indications

    Clinical phase

    New routes

     DHE (MAP004)

    Ergot alkaloid, delivered by inhalation

    Phase III

     Sumatriptan (NP101)

    5-HT1B/1D, transdermal patch

    Phase III

     Sumatriptan (Intraject needle-free system)

    5-HT1B/1D

    Phase II

    Combination approaches

     Rizatriptan and acetaminophen (paracetamol)

    5-HT1B/1D, simple analgesic

    Phase III–complete

     Rizatriptan and caffeine

    5-HT1B/1D, adenosine receptor antagonist

    Phase III–complete

    Pediatric indications

     Zolmitriptan

    5-HT1B/1D

    Adolescents

    Phase III

     Sumatriptan and naproxen

    5-HT1B/1D and NSAID

    Adolescents

    Phase III

     Rizatriptan

    5-HT1B/1D

    Children and adolescents

    Phase III

    Associated symptoms

     Sumatriptan and naproxen or eletriptan

    5-HT1B/1D and NSAID

    Absorption and gastric transit in and outside of an attack

    Phase I

     DHE (intranasal)

    Ergot alkaloid

    Migraine with cutaneous allodynia

    Phase IV

     Rizatriptan

    5-HT1B/1D

    Trigeminal unilateral cranial autonomic symptoms (lacrimation, eye redness, eyelid edema, nasal congestion or rhinorrhea, miosis or ptosis, forehead or facial sweating)

    Phase IV

     Rizatriptan

    5-HT1B/1D

    Rotational motion sickness in migraine patients

    Active

    Devices

     Transcranial magnetic stimulation

    Noninvasive device

    Phase III

     Direct transcranial stimulation

    Non-invasive device

    Phase II

    DHE dihydroergotamine, NSAID nonsteroidal anti-inflammatory drug

  • Designing new drug delivery systems for acute treatments has several advantages. For one, the safety profiles of the triptans and dihydroergotamine are already well established, so it is possible to bypass the lengthy preclinical stage and reduce the cost of drug developments. This section discusses alternative approaches to the older drugs.

Dihydroergotamine

ET is not routinely used in Western clinical practice because of its side-effect profile [50, Class I–III], but the structural alteration to DHE has resulted in greater tolerability, and it is more likely to cause venoconstriction than vasoconstriction. Intravenous DHE is safe and effective for the treatment of intractable headache [50, Class II]. Its mode of action may be related to its structural similarities with the biogenic amines and its relative affinities for serotonin, dopamine, and adrenergic receptors. Whether the primary mode of action is peripheral or central is a subject of debate, as is its ability to penetrate the blood-brain barrier. Experimentally, DHE has been shown to block neurovascular inflammation in the trigeminal nerve terminals [51]. Alternatively, a central theory of action has been proposed: stimulation studies of pain-producing structures such as the superior sagittal sinus or the middle meningeal artery result in an increase in the firing rate of the trigeminal nucleus caudalis, which can be inhibited by intravenous DHE [2] or local (ionophoretic) administration of ergometrine [52]. In further support of centrally mediated actions of DHE, Goadsby and Gundlach [53] directly detected the putative central sites of action of DHE and the extent to which it enters the brain through the autoradiographic localization of 3H-DHE-binding sites in the cat central nervous system, both in vitro and in vivo. In the spinal cord, specific binding was highest in the dorsal horn, whereas the strongest specific binding was in seen in the trigeminal nucleus caudalis. Predictably, the highest specific binding was seen in the midbrain in the distinct areas of the nucleus raphe dorsalis and, to a lesser extent, in the ventral periaqueductal gray, consistent with a central theory of the effect of these medications.

DHE administered by the intranasal route has a bioavailability of 40%, a rate that may be partly due to oropharyngeal deposits [54]. Oral inhaled DHE (MAP0004) provides a novel route of administration, using an inhaler that distributes the drug over a wider pulmonary surface area, therefore improving pulmonary systemic absorption. In a multicenter, randomized, double-blind phase III trial, DHE through oral inhalation with the new device met all primary end points and sustained pain freedom for up to 48 h, according to the company’s press release [55]. It is conceivable that DHE delivered through inhalation, currently in phase III clinical trials, is likely to become clinically useful in outpatient practice.

Triptans

Future developments within this class are largely being explored in connection with the development of new vehicles of administration. There are no active clinical investigations of novel triptans.

Combination approaches offer convenience, but they are not more likely to be effective than individual dosing. The oral formulation of sumatriptan 85 mg and naproxen sodium 500 mg is on the market [56, Class I], and other combinations of triptans with caffeine or acetaminophen are being tested (see Table 2).

New routes of administration are being tested. A transdermal formulation of sumatriptan completed a phase III study, which has not been completely published; at the most recent Congress of the International Headache Society, the company reported significant improvement over placebo in all key primary end points, with some adverse events at the patch site [57]. This approach may be practical, as nausea, vomiting and gastric stasis may limit the absorption of oral medications. Additional investigational delivery systems for sumatriptan include a new needle-free subcutaneous delivery system [58]. These alternative routes will be fruitful if they can reach peak plasma concentrations that will allow maximal efficacy with fewer vasoconstrictor side effects mediated by 5-HT1B.

Pediatric considerations

  • Migraine is common in pediatric populations, yet randomized controlled trials are few. Pediatric patients are generally considered to have less feature-full attacks. Unfortunately, many pharmaceutical options have not been as rigorously tested in these patients as in adults.

  • Sleep can be one treatment option, but when sleep is not effective, a simple analgesic may be tried [59].

  • One randomized controlled trial of sumatriptan nasal spray versus placebo in adolescents 12 to 17 years of age suggested that the 20 mg dose of sumatriptan was the most efficacious and provided the best tolerability profile [60, Class I].

  • In a more recent randomized controlled trial, almotriptan was considered most efficacious at a dose of 12.5 mg and was well tolerated [61, Class I]. Several ongoing triptan trials are seeking new indications in the pediatric population (Table 2). One important aspect of studies in this age group is the issue of expectation and its control use in a cross-over design [62].

Emerging devices

Trancranial magnetic stimulation and transcranial direct current stimulation

Transcranial magnetic stimulation (TMS) and transcranial direct current stimulation (tDCS) are two devices currently being investigated in clinical trials for treatment of acute migraine attacks. These devices have been used in other pain conditions, in which brain stimulation techniques seek to modulate activity in neuronal circuitry implicated in pain processing. Defective habituation, expressed as greater than normal amplitude of the evoked response to repeated stimulation, is observed in migraine, making stimulation devices a logical intervention worthy of clinical testing [63].

These devices target CSD, the wave of depolarization that travels from the occipital cortex (usually anteriorly), associated with an initial wave of hypoperfusion seen in migraine with aura and likely associated with migraine without aura, in which the aura may be clinically silent [64•].TMS is a noninvasive method by which weak electrical currents induce a magnetic field that generates small electrical currents. The electrical effects of TMS can be appreciated in an experimental rat model of CSD: in the study, the wave of neuronal excitation was shown to be blocked by over 50%, indicating that this may be an effective therapeutic option [65]. As some propose that CSD may trigger an attack by activating the trigeminovascular system in experimental models, CSD has been targeted [66]. Its not clear that targeting CSD will be the way forward, based on clinical trials of tonabersat, a neuronal-glial gap junction inhibitor, which reduced the aura but not the frequency of headaches in patients with migraine with aura [67].

Because spontaneous attacks may be initiated in the brainstem, deep neuromodulatory brainstem structures may be an alternative target site.

A randomized, double-blind, parallel-group, sham-controlled trial of single-pulse TMS for acute treatment of migraine with aura showed pain-free response rates at 2 h and sustained pain-free responses both at 24 h and 48 h after treatment [68]. The application of low-intensity current to the cerebral cortex using tDCS has been investigated and is now in phase II trials using tDCS versus sham tDCS in patients with migraine with or without aura and those with chronic migraine [69]. If proven effective and safe, these devices may be additional nonvasoconstrictive alternatives.

Disclosure

Conflicts of Interest: T. Monteith: none; P. Goadsby: Over the past 12 months, PJG has consulted for, advised, or collaborated with Advanced Bionics, Allergan, Almirall, Amgen, ATI, AstraZeneca, Belgian Research Council, Boehringer-Ingelheim, BMS, Boston Scientific, Colucid, Eli-Lilly, Fidelity Foundation, GlaxoSmithKline, Johnson & Johnson, Kalypsys, Medtronic, MAP, Migraine Research Foundation, Migraine Trust, Minster, Medical Research Council-UK, MSD, NINDS, Netherlands Research Council, Neuralieve, Neuraxon, NTP, Organisation for Understanding Cluster Headache-UK and US, and Pfizer.

Open Access

This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

Copyright information

© The Author(s) 2010